
The eye care community is moving toward a more disruption-resistant system of care, from wearable tech to VEGF-eluting implants.
Dr. Caldwell is an ocular disease consultant based in Johnstown, Pennsylvania. His primary focus is the diagnosis and management of anterior and posterior segment ocular disease, and he has been a participant in multiple FDA investigations. Caldwell consults for Bio-Tissue. This article was written without industry influence.
Phone: 814-931-2030
Email: grubod@gmail.com

The eye care community is moving toward a more disruption-resistant system of care, from wearable tech to VEGF-eluting implants.

Wearable devices and multifunctional instruments provide in-office advantages

With its anti-infective, anti-inflammatory, and regenerative properties, this versatile therapeutic should be in your toolbox.

A 68-year-old White woman was referred for persistent keratitis OS and failure on multiple medications. Find out her official diagnosis and treatment plan.

This drug category is rapidly growing in the ophthalmic space, with more options in the pipeline

Published: January 7th 2022 | Updated:

Published: January 7th 2022 | Updated: